CN102018721B - Chewable tablet of calcium carbonate dimeticone and preparation process - Google Patents
Chewable tablet of calcium carbonate dimeticone and preparation process Download PDFInfo
- Publication number
- CN102018721B CN102018721B CN2009102721884A CN200910272188A CN102018721B CN 102018721 B CN102018721 B CN 102018721B CN 2009102721884 A CN2009102721884 A CN 2009102721884A CN 200910272188 A CN200910272188 A CN 200910272188A CN 102018721 B CN102018721 B CN 102018721B
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- dimeticone
- chewable tablet
- preparation
- simethicone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a chewable tablet of calcium carbonate dimeticone and a preparation process, belonging to four new national chemical medicines. The preparation of the invention is prepared from the following main components: calcium carbonate, simethicone, siliciidoxydum, aspartame, essence powder, mannite, corn starch, low-substituted hydroxypropyl cellulose and magnesium stearate, wherein the calcium carbonate as the main content has stronger acid-resisting action and rapid and lasting effects, and the simethicone is a foam suppressor for eliminating gastrointestinal tract pneumatosis. The preparation is used for treating peptic ulcers including stomach and duodenal ulcer and easing various uncomfortable symptoms caused by hyperacidity.
Description
Technical field
The invention belongs to traditional Chinese medicines chemical drugs four kind new medicines.
Background technology
Peptic ulcer comprises gastric duodenal ulcer, is a kind of time-honored commonly encountered diseases, the sickness rate average out to 8-10% in the crowd.The reasonability of antacid and medication inexpensive because of it, and meet current national Health care system, be a kind of main medicine of treatment peptic ulcer.Antacid is generally alkaline compound, thus in vivo can in remove its stimulation and damage with gastric acid to the gastric duodenal ulcer face, can relief of symptoms, help the reparation of ulcer.Clinically compound recipes that adopt antacid and other drug to form, defoamer is a kind of for wherein more.Defoamer can be eliminated the foam in the gastrointestinal tract because surface tension is little, and the gas of being stored by foam is released, and alleviates flatulence, and the gastrointestinal tract flatulence that a variety of causes is caused has positive effect.This product is the compound preparation of antacid calcium carbonate and defoamer dimethicone.
Summary of the invention
The present invention has mainly provided prescription and the method for preparing that a kind of new antacid class is treated the chemical drugs of gastric duodenal ulcer, and said preparation prescription and method for preparing are domestic to be used as yet.
Prescription of the present invention is: calcium carbonate 420.0g; Dimethicone 20.0g; Micropowder silica gel 1.0g; Aspartame 3.0g; Powdered flavor 3.0g; Mannitol 200.0g; Corn starch 13.5g; Low-substituted hydroxypropyl cellulose 15.0g; Magnesium stearate 4.0g.
Method for preparing of the present invention is: formula ratio is pressed with dimethicone, micropowder silica gel mix homogeneously in (1), adds the calcium carbonate of crossing 120 mesh sieves again and fully mixes, and it is subsequent use to cross 40 mesh sieves.(2) other adjuvants of having crossed mesh sieve except that magnesium stearate are added in (1), cross 80 mesh sieve mix homogeneously.(3) add 5% starch slurry and process soft material, cross 16 orders and granulate.(4) put in 50 ℃ of baking ovens and dry.Press formula ratio in the granule and add magnesium stearate, cross 20 order granulate.Survey in the granule behind the drug content tabletting.
The specific embodiment
With reference to the Titralac of Minnesota Mining and Manufacturing Company
TMThe dosage formulation of plus Antacid chewable tablet is formed: every carbonated calcium 420mg, Simethicone 21mg, the wherein mixture of Simethicone dimethicone and silicon dioxide.Dimethicone is an active substance; The micropowder silica gel main component is a silicon dioxide, and to increase the distribution area of dimethicone, content is 4～7% as dispersant.Adopt external report method with 20mg dimethicone and 1mg micropowder silica gel mix homogeneously in this research, its semi-solid material is equivalent to Simethicone 21mg.
In the prescription screening process, because 3M company's T itralac
TMPlus Antacid chewable tablet both can be chewed, and can swallow again, so be index with mouthfeel, outward appearance and the disintegrate etc. of tablet mainly, investigated disintegrate emphatically, through selecting different auxiliary materials and consumption for use, confirmed more reasonably prescription.
Concrete screening process sees the following form.
Table 1: prescription screening
Annotate: L-HPC is that low-substituted hydroxypropyl cellulose, CMS-Na are for completing methyl starch sodium
Through prescription screening, the 4 gained tablet mouthfeels of filling a prescription.Outward appearance and disintegrate are all better.So select for use this prescription as end formulation.
Claims (1)
1. a calcium carbonate dimeticone chewable tablet is characterized in that, and is formulated by following material: antacid calcium carbonate 420.0g; Froth breaking medicine dimethicone 20.0g; Micropowder silica gel 1.0g; Aspartame 3.0g; Powdered flavor 3.0g; Mannitol 200.0g; Corn starch 13.5g; Low-substituted hydroxypropyl cellulose 15.0g; Magnesium stearate 4.0g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018721A CN102018721A (en) | 2011-04-20 |
| CN102018721B true CN102018721B (en) | 2012-08-22 |
Family
ID=43860771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102721884A Active CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018721B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523717A (en) * | 2015-01-06 | 2015-04-22 | 西南大学 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
| CN106860475A (en) * | 2017-02-17 | 2017-06-20 | 北京沃邦医药科技有限公司 | A kind of preparation method of calcium carbonate D3 tablets |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170358A (en) * | 1994-12-16 | 1998-01-14 | 沃特森实验室公司 | Chewable dosage forms |
-
2009
- 2009-09-23 CN CN2009102721884A patent/CN102018721B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170358A (en) * | 1994-12-16 | 1998-01-14 | 沃特森实验室公司 | Chewable dosage forms |
Non-Patent Citations (3)
| Title |
|---|
| 徐凌云等.复方二甲基硅油咀嚼片治疗急性消化系统症状的临床研究.《中国临床药理学与治疗学》.2005,第10卷(第1期), * |
| 徐可树等.复方二甲基硅油对功能性肠胀气的疗效观察.《世界华人消化杂志》.2004,第12卷(第7期), * |
| 施昕磊等.咀嚼片的研究进展.《中国药业》.2008,第17卷(第14期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018721A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI257311B (en) | Rapidly disintegrable solid preparation | |
| RO118563B1 (en) | Dosed oral composition with instantaneous decomposition, and process for obtaining the same | |
| MXPA04000223A (en) | Novel substituted benzimidazole dosage forms and method of using same. | |
| JP2009292843A (en) | Solid pharmaceutical preparation | |
| CN1225017A (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
| JP2001513801A (en) | Swallow tablets containing paracetamol | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN102018721B (en) | Chewable tablet of calcium carbonate dimeticone and preparation process | |
| JP4939680B2 (en) | Solid preparation | |
| CN102512402B (en) | Novel preparation of medicine for treating gastric and duodenal ulcers and preparation method thereof | |
| JP2017119655A (en) | Orally disintegrating tablet containing lanthanum carbonate | |
| WO2000035418A2 (en) | Chewable drug delivery system | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN102872024B (en) | Misoprostol medicine combination used in mouths | |
| CN101269055B (en) | Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same | |
| CN101234094B (en) | Dipyridamole orally disintegrating tablet | |
| CN100471497C (en) | Naloxone Hydrochloride nose powder preparation | |
| CN103301467A (en) | Stable taste-masking ambroxol hydrochloride compound and preparation method thereof | |
| CN101099747A (en) | Compound alginic acid chewing tablet and preparation method thereof | |
| CN101574320A (en) | Intestinal protection medicament and preparation method thereof | |
| CN100394917C (en) | Bilobanoate oral-cavity disintegrating tablet and preparation method | |
| CN103877036A (en) | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof | |
| CN102488708B (en) | Magaldrate chewable tablets and preparation method thereof | |
| CN102370621A (en) | Solid preparation with cefotiam hexetil as active component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200810 Address after: 430000 Guannan science and Technology Industrial Park, Donghu Development Zone, Wuhan City, Hubei Province Patentee after: Hubei Huquan Pharmaceutical Co.,Ltd. Address before: 430073, No. 81 Nanhu Avenue, Guan Nan Industrial Park, East Lake New Technology Development Zone, Hubei, Wuhan Patentee before: HUANGSHI LISHIZHEN PHARMACEUTICAL GROUP WUHAN LISHIZHEN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |